BRIEF-Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 Guidance

Reuters12-10

Dec 10 (Reuters) - Ligand Pharmaceuticals LGND.O:

LIGAND HOSTS 2024 INVESTOR AND ANALYST DAY AND INTRODUCES 2025 GUIDANCE
LIGAND PHARMACEUTICALS INC -2025 FULL YEAR REVENUE GUIDANCE OF $180 MILLION TO $200 MILLION
LIGAND PHARMACEUTICALS INC - OUTLOOK 2025 FULL YEAR CORE ADJUSTED EARNINGS PER DILUTED SHARE OF $6.00 TO $6.25
LIGAND PHARMACEUTICALS INC -WILL REITERATE ITS 2024 GUIDANCE OUTLINED IN NOVEMBER

Source text: ID:nBwcgVMZNa

Further company coverage: LGND.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490015029?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490015029","market":"us","top_or_hot":-1,"title":"BRIEF-Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 Guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 Guidance</title></head><body><p><span>Dec 10 (Reuters)</span><span> - </span>Ligand Pharmaceuticals <span>LGND.O</span>:</p><ul><li><p>LIGAND HOSTS 2024 INVESTOR AND ANALYST DAY AND INTRODUCES 2025 GUIDANCE</p></li><li><p>LIGAND PHARMACEUTICALS INC -2025 FULL YEAR REVENUE GUIDANCE OF $180 MILLION TO $200 MILLION</p></li><li><p>LIGAND PHARMACEUTICALS INC - OUTLOOK 2025 FULL YEAR CORE ADJUSTED EARNINGS PER DILUTED SHARE OF $6.00 TO $6.25</p></li><li><p>LIGAND PHARMACEUTICALS INC -WILL REITERATE ITS 2024 GUIDANCE OUTLINED IN NOVEMBER</p></li></ul><p>Source text: <span>ID:nBwcgVMZNa</span></p><p>Further company coverage: <span>LGND.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA5JGSB:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 GuidanceDec 10 (Reuters) - Ligand Pharmaceuticals LGND.O:LIGAND HOSTS 2024 INVESTOR AND ANALYST DAY AND INTRODUCES 2025 ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA5JGSB:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1559883803.SGD","symbol_name":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA5JGSB:1","article_id":"2490015029","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490015029","pubTimestamp":1733839538,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 GuidanceDec 10 (Reuters) - Ligand Pharmaceuticals LGND.O:LIGAND HOSTS 2024 INVESTOR AND ANALYST DAY AND INTRODUCES 2025 GUIDANCELIG","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4139":"生物科技","BK4007":"制药","LGND":"Ligand Pharmaceuticals Inc.","LU0566484027.USD":"安本美国小盘成长股"},"translate_title":"BRIEF-Ligand举办2024年投资者和分析师日并介绍2025年指导","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":0.9},"content_text":"BRIEF-Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 GuidanceDec 10 (Reuters) - Ligand Pharmaceuticals LGND.O:LIGAND HOSTS 2024 INVESTOR AND ANALYST DAY AND INTRODUCES 2025 GUIDANCELIGAND PHARMACEUTICALS INC -2025 FULL YEAR REVENUE GUIDANCE OF $180 MILLION TO $200 MILLIONLIGAND PHARMACEUTICALS INC - OUTLOOK 2025 FULL YEAR CORE ADJUSTED EARNINGS PER DILUTED SHARE OF $6.00 TO $6.25LIGAND PHARMACEUTICALS INC -WILL REITERATE ITS 2024 GUIDANCE OUTLINED IN NOVEMBERSource text: ID:nBwcgVMZNaFurther company coverage: LGND.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490015029"}